BCR and malaria: More recent studies using malaria, HIV, or SARS-CoV-2 antigen-specific transgenic B cell receptor (BCR) knock-in mouse models have demonstrated that high titers of epitope-specific and high-affinity antibodies limit activation of the cognate naïve and memory B cells likely through epitope masking (McNamara et al., 2020; Tas et al., 2022).